N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer
Status:
Withdrawn
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
RATIONAL FOR STUDYING IV NAC AS POTENTIAL CHEMOPROTECTANT:
Cisplatin has shown efficacy in the treatment of subjects with epithelial ovarian cancer.
Systemic toxicities associated with cisplatin include nephro, oto, and nerve toxicities. It
may be possible to reduce the toxicities of cisplatin by administering it in conjunction with
IV NAC. NAC may reduce cisplatin related nephro, oto, and nerve toxicities without
compromising the effectiveness of the chemotherapy against the ovarian cancer cells. It is
possible that this combination of drugs may in the future allow ovarian cancer patients to
receive the full series of IP cisplatin-paclitaxel chemotherapy, with fewer side effects and
improved survival.
It is hypothesized that the proposed treatment of stage III or IV epithelial ovarian cancer
with IP cisplatin and IV/IP paclitaxel in conjunction with IV NAC will limit the
neurotoxicity, nephrotoxicity and ototoxicity that is associated with cisplatin
administration.